Found 62 clinical trials
The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs
This study sought to investigate the efficacy and safety of a three-drug combination antiemetic regimen of olanzapine combined with aprepitant and palonosetron for the prevention of chemoradiotherapy-induced nausea and vomiting in locally advanced head and neck squamous cell carcinoma.
- 0 views
- 21 Mar, 2022
HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
This is a single arm Phase I study of de-intensified hypofractionated radiation therapy for favorable human papilloma virus-associated oropharynx cancer. It will evaluate the tolerability of a de-intensified hypofractionated radiation therapy regimen completed in 3 weeks (with equivalent biologically effective dose to 60 Gy in 30 fractions) with concurrent weekly …
- 0 views
- 22 Mar, 2022
- 1 location
Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.
This clinical study is going to be done on a type of brain tumor in children called Medulloblastoma. The WNT pathway type of medulloblastoma is considered to be low risk and have the best outcomes in terms of survival. With the current standard of care for this type of medulloblastoma …
- 0 views
- 13 Oct, 2021
- 1 location
Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom
The goal of this study is to test whether a new device developed at UAB can decrease the error in calculating blood flow of a brain tumor, leading to better prognosis. UAB radiological research team has been studying a cutting-edge imaging technique named dynamic contrast enhanced magnetic resonance imaging, or …
- 0 views
- 25 Mar, 2022
- 1 location
Hypofraction Radiotherapy for Limited-Stage Small Cell Lung Cancer
Concurrent chemoradiotherapy is the standard modality for locally advanced small-cell lung cancer, which could achieve median overall survival of 25 mos. Conventional fractionation of 66Gy/33f and hyperfractionation of 45Gy/30f twice daily have been acknowledged as the two standard radiotherapy modalities according to CONVERT study. In 2021, a phase II trial …
- 0 views
- 07 Oct, 2022
- 1 location
To Observe the Benefit of Adding Brachytherapy After CCRT on Resectable Esophageal Cancer Patients Without Surgery
Clinical experience of adding intraluminal brachytherapy with traditional applicator after definitive concurrent chemoradiotherapy (CCRT) for local-regional thoracic esophageal cancer is limited due to high complication risk and non-superiority in survival. The innovative applicator can maximize the therapeutic efficacy by reducing dose inhomogeneity in the esophageal wall, which will translate into …
- 0 views
- 15 Dec, 2021
- 1 location
Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
In this Phase 1/2 study, the investigators will conduct a safety and efficacy study of the combination of BMX-001 with standard radiation therapy (RT) and concurrent 5-fluorouracil (5FU)/mitomycin in newly diagnosed Anal Squamous Cell Carcinoma (ASCC) patients. The primary objectives are: Phase 1 - is to determine the maximum tolerated …
- 7 views
- 29 Jul, 2023
- 1 location
Pneumonitis After Radiotherapy for Lung Cancer
Major goals of radiotherapy include local disease control and improvement of the patients' prognoses. One possible side effect of radiotherapy for lung cancer is radiation pneumonitis. Severe (grade 3) radiation pneumonitis can even be fatal in approximately 2% of the patients. It would be important to identify patients developing radiation …
- 0 views
- 09 May, 2021
- 1 location
Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial
The purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC
- 19 views
- 20 Oct, 2022
- 1 location
A Randomized Phase II Trial of TPF Induction Chemotherapy in cN2 Patients With Oral Squamous Cell Carcinoma
To confirm the subgroup result from TPF (docetaxel, cisplatin and 5-fluorouracil ) trial (NCT01542931) that cN2 OSCC patients could benefit from TPF induction chemotherapy compared to the standard treatment.
- 0 views
- 20 Oct, 2022
- 1 location